October 21, 2019 by Amanpreet
According to U.S. National Library of Medicine, the prevalence rate of TTP is in the range of 1.7 to 11 cases per million population in the U.S. In addition to TTP, increase in prevalence of autoimmune diseases and advancement in plasmapheresis is likely to drive the growth of the market during the assessment period in the U.S. The market in Europe is likely to mimic the U.S. in terms of key driving factors, whereas greater emphasis on boosting healthcare infrastructure is likely to fuel market growth in Asia Pacific excluding Japan (APEJ) and Latin America. In terms of revenues, North America will continue to be a leading market, with U.S. accounting for the bulk of revenues. The U.S. is home to some of the leading companies in the plasmapheresis market, and there is a high emphasis on research and development among universities and institutes. Collaboration between companies and institutions has also contributed to the growth of the market in the region.
Read Report Summary: https://www.factmr.com/report/351/plasmapheresis-market
Request for Report Methodology: https://www.factmr.com/connectus/sample?flag=RM&rep_id=351
To learn more about how the key growth influencers are shaping the market landscape, request for the Sample Report at: https://www.factmr.com/connectus/sample?flag=S&rep_id=351